Last reviewed · How we verify
NCT07192679: MAGNIFY
MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis
trial in Cystic Fibrosis (CF) in 80 participants. Currently enrolling.
1 January 2028
Quick facts
| Lead sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 21 February 2024 |
| Primary completion | 1 January 2028 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Cystic Fibrosis (CF) — all drugs for Cystic Fibrosis (CF) →
Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Who can join
1 and older, any sex, with Cystic Fibrosis (CF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is looking at new ways of measuring the function of the lungs in patients with cystic fibrosis. This study is using the most advanced methods for measuring lung function including 2 tests called hyperpolarised gas magnetic resonance imaging (HP MRI) and multiple breath washout (MBW), to better understand changes in the lungs over time. HP MRI involves taking pictures of the air in your lungs after breathing in a harmless gas (xenon). MBW is a breathing test used to calculate something called the lung clearance index (LCI). By measuring these tests on the same day, alongside standard lung function tests, we aim to understand lung function in greater detail than ever before.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07192679
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis (CF)
Currently open trials in the same condition.
- NCT07303621 — Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population · recruiting
- NCT07071324 — CF Wellness Program · NA · recruiting
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT07363304 — Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People Wi · recruiting
- NCT07508904 — Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis · NA · recruiting
Other Sheffield Teaching Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407712 — Better Outcomes Through Optimal Sleep in Surgical Training · NA · recruiting
- NCT07172555 — Virtual Dietetic Interventions in Patients With Coeliac · NA · recruiting
- NCT06310993 — Exercise to Boost Immunity in Advanced Cancer · NA · not yet recruiting
- NCT06905405 — The Use of Advanced Imaging in HFpEF · recruiting
- NCT06633627 — Neurological Responses in Patients with Dentine Hypersensitivity · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07192679 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheffield Teaching Hospitals NHS Foundation Trust
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07192679.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing